AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 262 min read$PCVX

PICKERING GRANT sold $1.2M of PCVX

PICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 22,237 shares of Vaxcyte, Inc. (PCVX) at an average of $55.21 ($54.28–$56.12, $1.23M total) across 3 trades on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PICKERING GRANT
Published Jun 26, 2026, 10:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
medium confidence
Mentioned
$PCVX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The CEO’s open-market sale totals ~$1.23M across three trades at ~$54.28–$56.12/share, with a stated pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh, primary-source datapoint on insider selling, but the 10b5-1 framing limits fundamental interpretation.

03

What to watch

The filing does not disclose reasons for sale; traders should compare with prior insider activity and the company’s upcoming catalysts (earnings/clinical updates) rather than over-weighting this single transaction.

Relevance 5/10Novelty 5/10Timing: filed 2026-06-26 (same day as insider sale)

Background

The article is an SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX).

Company-level read

Ticker impact

$PCVXNeutralMedium confidence
Context

SEC Form 4 shows Vaxcyte CEO Pickering Grant sold 22,237 shares in open-market trades for ~$1.23M on 2026-06-26.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than new fundamentals.

Evidence & confidence

The filing is primary-source and same-day, but it explicitly cites a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • issuer
    Vaxcyte, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Pickering Grant

    CEO and director who sold shares in open-market trades.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

OCT 9
$PCVXHighAI 9/10

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte (PCVX) closed public offerings raising $1.15B, including 8.58M shares at $64 each, pre-funded warrants, and $575M in convertible notes. Proceeds will fund clinical trials, manufacturing, and R&D. Joint bookrunners included Jefferies, Leerink, and BofA.

marketscreener.com2 min
OCT 9
$MRNAHighAI 8/10

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally - Moderna (NASDAQ:MRNA), BioNTec

A new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.

benzinga.com2 min